Dialysis treatment in patients with rheumatoid arthritis.
The results of dialysis treatment in 24 rheumatoid arthritis patients, 20 chronic rheumatoid arthritis (RA) and 4 juvenile rheumatoid arthritis (JRA), were analysed. Presence of secondary amyloidosis, renal function, morbidity and survival were examined. Amyloidosis was present in 13 patients. Especially among amyloidosis patients, renal function declined rapidly in the last year before dialysis started. On average, 63 days per patient-year were spent in the hospital, 58% was dialysis-related, mainly due to vascular access problems. Hospitalization was even more widespread in amyloidosis patients (79 days, 72% dialysis-related). Median survival in RA patients with amyloidosis was 11 months; in RA patients without amyloidosis this was 29 months. Two-year survival was only 1 out of 10 for the RA amyloidosis patients; for the RA non-amyloidosis patients this was 5 out of 6 (p < 0.01). Cardiovascular causes of death were most frequent. In conclusion, high morbidity and low survival make RA patients with amyloidosis a high-risk group on renal replacement therapy.
Hezemans
R L
RL
Department of Internal Medicine, Academic Medical Centre, Amsterdam, Netherlands.
Krediet
R T
RT
Arisz
L
L
D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000150:complications*; D001171:Arthritis, Juvenile / Q000150:complications / Q000401:mortality; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D010531:Peritoneal Dialysis, Continuous Ambulatory; D012189:Retrospective Studies; D015996:Survival Rate